Participated · Series C · Jun 2026

Rejoni is focused on developing and commercializing gynecological products built on proprietary biomaterials, with its lead investigational product the Juveena Hydrogel System. Juveena is designed to reduce the incidence and severity of intrauterine adhesions by placing a temporary hydrogel spacer in the uterine cavity using a proprietary transcervical catheter. The product is investigational and pending U.S. FDA approval and is not available for sale. Rejoni is clinical-stage and plans to scale manufacturing, supply operations, and market-access and physician/patient engagement in preparation for commercial launch. The company was founded in June 2020 in Bedford, MA; Amar Sawhney is founder and chairman and John Nealon is CEO. The recent $25 million financing will support these commercialization and regulatory preparations.

Participated · Series E · Jun 2026

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Participated · Series A · May 2026

Kanvas Biosciences develops a spatial biology platform for microbiome drug screening, discovery and manufacturing aimed at accelerating live biotherapeutics development. The company’s lead program is KAN-001, an immuno-oncology candidate for which the recent Series A will fund clinical trials. Kanvas intends to use proceeds to advance commercial partnerships alongside clinical development. Its core technology was initially developed at Cornell University and is exclusively licensed. The company is led by CEO Matthew Cheng. The articles do not report revenue, user metrics, founding year, or prior financing details.

Participated · Series C · Oct 2024

Evommune is a Palo Alto-based clinical-stage biotechnology company focused on discovering and developing treatments for immune-mediated inflammatory diseases. Led by CEO Luis Pena, its lead programs include EVO756, a potent, highly selective small-molecule antagonist of MRGPRX2, and EVO301, a long-acting serum albumin-binding injectable therapeutic fusion-protein targeting IL-18 signaling. EVO756 is implicated in mast cell activation and neuroinflammation and is being developed as a potentially targeted, safe oral therapy for multiple mast cell–mediated diseases. EVO301 is designed to neutralize IL-18 signaling to regulate inflammation across chronic inflammatory diseases. The company plans multiple Phase 2 studies of EVO756 and a Phase 2 proof-of-concept study of EVO301. Evommune raised $115M in a Series C and intends to use the proceeds to advance these lead clinical programs. Evommune is a private, clinical-stage R&D biotechnology company focused on treating inflammatory diseases. The company uses a human tissue–based approach to discover, develop, and deliver therapies intended to address symptoms and halt progressive disease. Led by President and CEO Luis Peña, Evommune pursues translational immunology research to advance its therapeutic candidates. Founded in 2020, the company is advancing its pipeline through clinical-stage development. Evommune recently expanded funding for its Series B round, strengthening its financial position for near-term work. The company intends to use the new funds to expand operations and broaden its business reach. Evommune is a clinical-stage biotechnology company discovering and developing therapies to treat inflammatory diseases using a dynamic human tissue-based approach. Its prioritized pipeline includes EVO101, a novel small-molecule IRAK4 inhibitor currently in a Phase 2a proof-of-concept trial for atopic dermatitis, with data expected later this year. The company is also developing EVO756, a preclinical program that targets mast cells by selectively modulating MRGPRX2 to treat chronic spontaneous urticaria and interstitial cystitis. In addition, Evommune runs a discovery program targeting autoimmune diseases via PKCθ. The company intends to use the proceeds from its recent financing to support these three prioritized programs. Evommune was founded in 2020 and is led by President and CEO Luis Peña in Palo Alto, CA. Evommune is a private R&D company and innovation engine that uses the skin as a lens to uncover approaches for accelerating development of medicines across immunology and dermatology. The company has four investigational compounds in its pipeline, three of which were in‑licensed via an exclusive agreement with Dermira, a wholly owned subsidiary of Eli Lilly and Company. Evommune is led by co‑founders Luis Pena (President & CEO), Eugene A. Bauer, M.D. (Chief Medical Officer), and Hans Hofland, PhD (SVP of Research). The company says it is developing transformative therapies to treat patients with immune‑mediated and chronic inflammatory diseases. Evommune recently won the Gore Range Capital Skin Health Innovation Competition at the Fall Clinical Dermatology Conference, reflecting engagement with clinicians and industry thought leaders. The company plans to use its recent funding to continue research and development of its pipeline. Evommune applies a tissue‑based, skin‑centered approach and a novel screening platform to discover molecules aimed at treating chronic inflammatory and dermatologic diseases. The company is building a pipeline intended to include both discovery-stage and clinical‑stage development programs and has established academic and industry collaborations to support that work. Leadership includes industry veterans Luis Peña (CEO), Eugene A. Bauer, MD (CMO), Hans Hofland, PhD (SVP, research), and Janice Drew, MPH (SVP, product development), who previously held senior roles at Dermira. The team highlights a track record of rapid regulatory approvals and drug development across immunology and dermatology; Dermira was sold to Eli Lilly for approximately $1.1 billion in 2020. Evommune says the seed financing will be used to set up and drive execution of its longer‑term strategy to accelerate development of transformative medicines. The company was founded in 2020 and is headquartered in Los Altos, California.

Participated · Seed · Sep 2024

Cercle’s core product is the Cercle Biomedical Graph™, an AI-driven platform that ingests and transforms raw, de-identified women’s healthcare data into high-quality, real-time insights. The Graph acts as a mediator between patient records and LLMs, anonymizes data, and is HIPAA- and GDPR-compliant. Since its November 2023 introduction the platform has been used by US Fertility, Boston IVF, and Eurofins Genoma and has captured and analyzed more than one billion anonymized data points. Cercle will use the seed funding to expand beyond the fertility market, broaden its global footprint, and advance its LLM capabilities and product engineering. The company aims to serve providers, payers, and pharma across reproductive health, menopause, women’s oncology, and rare diseases that disproportionately affect women. The company notes the Graph has not been evaluated by the FDA and is not classified as a medical device.